US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over allegations of trade secret misappropriation. According to a security exchange notice from InventisBio, Mirati has filed a lawsuit in the Shanghai Intellectual Property Court, requesting an injunction, damages, and confirmation of ownership of certain patents. Mirati is seeking damages of RMB 99 million (USD 14 million).
Lawsuit Details
Mirati specifically alleges that certain patents awarded to InventisBio for a preclinical project infringe on Mirati’s own research and should be owned by Mirati. The lawsuit highlights the ongoing legal disputes in the biotechnology sector, where intellectual property rights are a critical asset.
Company Profiles
Both Mirati and InventisBio focus on the development of targeted small-molecule therapies for cancer and other therapeutic areas. Mirati’s lead pipeline candidate is the KRASG12C-targeted adagrasib (MRTX849), while its preclinical/discovery candidates include an SOS1 Inhibitor (KRAS signal modifying) and a mutant KRAS inhibitor. Meanwhile, InventisBio’s pipeline includes molecules targeting EGFR, KRASG12C, SERD, and others. This legal action underscores the competitive landscape in oncology research and the importance of protecting intellectual property.
Future Implications
The lawsuit between Mirati and InventisBio highlights the complexities of intellectual property disputes in the global biotechnology industry. As both companies continue to advance their pipelines, the outcome of this case could have significant implications for their respective development strategies and market positions.-Fineline Info & Tech
